Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 07 May 2014 | By Alexander Gaffney, RAC,
A new draft guidance document issued by the US Food and Drug Administration (FDA) is intended to provide clearer expectations for developers of therapies to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
The guidance, Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment, replaces an earlier 2010 guidance by the same name in the hopes of providing additional and updated details about appropriate clinical endpoints, enrollment criteria and noninferiority margin justifications.
For example, FDA explains in the guidance it is primarily interested a drug showing superiority relative to a control drug, though noninferiority trials may also be acceptable as evidence of effectiveness. A single, well-controlled trial might be sufficient to provide evidence of effectiveness, FDA indicated, but the trial parameters should be discussed with FDA prior to the trial being initiated.
FDA also recommends that companies should assemble a preapproval safety database involving, at a minimum, 500 patients.
The guidance also devotes significant attention to endpoints. FDA explained that sponsors should select one of two potential primary endpoints:
As BioCenturyexplains, the guidance leaves out a primary endpoint of clinical response that was recommended in 2011 by an advisory committee, but retains it as a secondary endpoint.
As with two earlier guidance documents on antibiotic development, FDA also said it would allow the enrollment of patients even if they had been previously treated with antibiotics. However, patients who have received treatment with an antibiotic within the past 24 hours will not be allowed to enroll.
Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment (FR)
Tags: Pneumonia, Antibiotic, Antibacterial, Latest News, draft guidance, guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.